Sustained release ocular drug delivery systems for glaucoma therapy

Area of Science:

• Ophthalmology
• Drug Delivery Systems
• Glaucoma Research

Background:

• Glaucoma is a leading cause of irreversible blindness characterized by optic nerve damage and elevated intraocular pressure (IOP).
• Conventional ocular hypotensive eye drops are a common treatment, but patient adherence and side effects pose significant challenges to managing glaucoma progression.
• Inadequate patient education further complicates effective glaucoma management.

Purpose of the Study:

• To review and discuss sustained-release drug delivery systems for glaucoma treatment.
• To highlight the potential of these systems in improving patient adherence and preventing vision loss.
• To emphasize the need for large-scale trials to establish the efficacy and safety of sustained-release platforms.

Main Methods:

• Classification of sustained-release systems into extraocular (e.g., ocular inserts, contact lenses) and intraocular (e.g., implants, microspheres) categories.
• Review of applications for both small molecules and biologics in ocular hypotensive drug delivery.
• Discussion of challenges and future directions for sustained-release technologies in glaucoma management.

Main Results:

• Sustained-release platforms can potentially enhance patient adherence to glaucoma medications.
• These systems may offer a method to reverse or prevent vision deterioration associated with glaucoma.
• Improved clinical management and prognosis for glaucoma patients are anticipated with the adoption of these technologies.

Conclusions:

• Sustained-release drug delivery systems represent a significant advancement in glaucoma therapy.
• Widespread adoption hinges on demonstrating robust efficacy and safety through extensive clinical trials.
• These innovative approaches hold the potential to revolutionize glaucoma treatment and improve patient outcomes.